The Prognostic Value of Derivatives-Reactive Oxygen
Metabolites (d-ROMs) for Cardiovascular Disease Events and
Mortality: A Review
Oxidative stress participates in the development and exacerbation of cardiovascular diseases (CVD). The ability to promptly quantify an imbalance in an individual reductive-oxidative (RedOx) state could improve cardiovascular risk assessment and management. Derivatives-reactive oxygen metabolites (d-ROMs) are an emerging biomarker of oxidative stress quantifiable in minutes through standard biochemical analysers or by a bedside point-of-care test. The current review evaluates available data on the prognostic value of d-ROMs for CVD events and mortality in individuals with known and unknown CVD. Outcome studies involving small and large cohorts were analysed and hazard ratio, risk ratio, odds ratio, and mean differences were used as measures of effect. High d-ROMs plasma levels were found to be an independent predictor of CVD events and mortality. Risk begins increasing at d-ROMs levels higher than 340 U.CARR and rises considerably above 400 U.CARR. Conversely, low d-ROMs plasma levels are a good negative predictor for CVD events in patients with coronary artery disease and heart failure. Moreover, combining d-ROMs with other relevant biomarkers routinely used in clinical practice might support a more precise cardiovascular risk assessment. d-ROMs represent an emerging oxidative-stress-related biomarker with the potential for better risk stratification both in primary and secondary cardiovascular prevention.
The d-ROMs test can be a useful prognostic test in cardiovascular medicine.
(+39) 0521 462607